Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 4, 2007, Pages 1062-1066

  Fang, Lei ^a,b   Zhang, Yihua ^a   Lehmann, Jochen ^b   Wang, You ^a   Ji, Hui ^a   Ding, Dayong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Anti inflammatory activity; Furoxan; Glucocorticoids; Hydrocortisone; NO donors; Safety

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; NITRIC OXIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMICAL REACTION; DRUG DESIGN; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HYPERTENSION; NONHUMAN; OSTEOPOROSIS;

ALKALINE PHOSPHATASE; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; BLOOD PRESSURE; CARRAGEENAN; CELL PROLIFERATION; COTTON FIBER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; EDEMA; GLUCOCORTICOIDS; HEART RATE; MICE; NITRIC OXIDE; OSTEOBLASTS; OSTEOCLASTS; OXADIAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; XYLENES;

EID: 33846597467     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.11.018     Document Type: Article

References (17)

1. Schäcke H., Döcke W.D., and Asadullah K. Pharmacol. Ther. 96 (2002) 23
2. Moncada S., Palmer R.M., and Higgs E.A. Pharmacol. Rev. 43 (1991) 109
3. Wallace J.L., Ignarro L.J., and Fiorucci S. Nat. Rev. Drug Disc. 1 (2002) 375
4. Fiorucci S., Santucci L., and Gresele P. Gastroenterology 124 (2003) 600
5. Loretta L., Barbara R., Marco L.L., Gian C.T., Roberta F., Alberto G., Guido D., and Harald L.G. J. Med. Chem. 48 (2005) 1322
6. Medana C., Di Stilo A., Visentin S., Fruttero R., Gasco A., Ghigo D., and Bosia A. Pharm. Res. 16 (1999) 956
7. Pier G.B., Romeo R., Maria C.N., Mauro P., Mark J.P., Massimiliano F., Mirco G., Francesca B., and Ennio O. J. Med. Chem. 47 (2004) 711
8. 14S): C, H, N.
9. Sorba G., Ermondi G., Fruttero R., Galli U., and Gasco A. J. Heterocycl. Chem. 33 (1996) 327
10. 2), 7.26-7.30 (m, 2H, C(3)-H, C(5)-H), 7.43-7.46 (m, 2H, C(2)-H, C(6)-H), 7.62-7.65 (m, 2H, C(3′)-H, C(5′)-H), 7.68-7.76 (m, 1H, C(4′)-H), 8.09-8.12 (m, 2H, C(2′)-H, C(6′)-H).
11. Wimalawansa S., Chapa T., and Fang L. J. Bone Miner. Res. 15 (2000) 1119
12. -7 mol/L were added to the medium; each concentration repeated in 4 wells. One vehicle control group was also performed. 48 h later the medium was removed and 200 μL of 1% aqueous solution of Triton X-100 was supplemented. The cells were kept in a refrigerator at 4 °C for 1 h. Thus the activity of ALP was measured by the commercially available kits using the method described by the manufacturer.
13. Garrett, R.I. WO 2003105752, 2003, 12-24.
14. -7 mol/L were added to the medium and at each concentration repeated in 4 wells. One vehicle control group was also incubated. To measure the numbers of tartrate-resistant acid phosphatase (+) (TRAP) cells, the cells were incubated with tested compounds for 48 h. Cells were then stained with the osteoclast-associated enzyme TRAP. Five milligrams of naphthol AS-MX phosphate was resolved in 0.5 ml of N,N-dimethylformamide, after which 30 mg of fast red violet LB salt and 50 ml of 0.1 M sodium acetate buffer (pH 5.0) containing 50 mM sodium tartrate were added to the TRAP-staining solution. The coverslips were fixed with 10% formalin for 10 min and then incubated with TRAP-staining solution for 1 h at 37 °C. The number of TRAP-positive cells was counted to estimate the degree of macrophageosteoclast differentiation.
15. Das U.N. Exp. Biol. Med. 227 (2002) 88
16. Wimalawansa S.J., De Marco G., Gangula P., and Yallampalli C. Bone 18 (1996) 301
17. 6 (31.0 mg/kg), Hyc (43.4 mg/kg) and CMC-Na, respectively, for 3 weeks. Then after 1 h since the last treatment of the drugs, the blood pressure of each mouse was determined by the BESN system of multi-channel tail-artery blood pressure measurement. Plasma samples were then collected from the femoral artery and serum NO (μmol/L) was measured using a nitrate reductase assay.